Saudi ArabiaTuberculosis profile
Population  2015 32 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.66 (0.21–1.4) 2.1 (0.66–4.3)
Mortality (HIV+TB only) 0.018 (<0.01–0.09) 0.06 (0–0.28)
Incidence  (includes HIV+TB) 3.8 (3.3–4.4) 12 (10–14)
Incidence (HIV+TB only) 0.14 (0.11–0.16) 0.43 (0.36–0.51)
Incidence (MDR/RR-TB)** 0.15 (0.12–0.18) 0.48 (0.38–0.57)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.17 (0.11–0.23) 1.1 (0.66–1.5) 1.3 (0.77–1.7)
Males 0.13 (0.087–0.17) 2.5 (1.9–3) 2.6 (2–3.2)
Total 0.3 (0.22–0.38) 3.5 (3.2–3.9) 3.8 (3.3–4.4)
TB case notifications, 2015  
Total cases notified 3 464
Total new and relapse 3 346
          - % tested with rapid diagnostics at time of diagnosis 23%
          - % with known HIV status 51%
          - % pulmonary 76%
          - % bacteriologically confirmed among pulmonary 84%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.18 (0.06–0.37)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 69 4%
          - on antiretroviral therapy    
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  110
(91–130)
Estimated % of TB cases with MDR/RR-TB 2.6% (2–3.2) 20% (16–25)  
% notified tested for rifampicin resistance 34% 36% 1 186
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 45, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 45, XDR-TB:
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 62% 3 248
Previously treated cases, excluding relapse, registered in 2014 33% 88
HIV-positive TB cases, all types, registered in 2014 27% 63
MDR/RR-TB cases started on second-line treatment in 2013    
XDR-TB cases started on second-line treatment in 2013    
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 6%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-09 Data: www.who.int/tb/data